Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Denali Therapeutics IncDNLI | $24.93 | Strong Buy | $35.00 | +40.39% | 21 hours ago | |
Analyst RankingTop 3% #163 out of 5498 analysts Average Return+32.85% Win Rate50%79 out of 159 Risk vs RewardPoor Good Analyst ColorB. Riley Securities's Mayank Mamtani raised their price target on Denali Therapeutics (NASDAQ: DNLI) by 16.7% from $30 to $35 on 2026/08/25. The analyst maintained their Strong Buy rating on the stock. Contextualizing their price target hike on Denali Therapeutics, Mamtani observed that: The AVLAYAH* launch is going according to plan, with QTD sales ahead of estimates. A peak U.S. Hunter revenue opportunity of $200M supporting the company's broader platform and future neurodegeneration program
Footnotes* AVLAYAH is a prescription-only enzyme replacement therapy (ERT) called tividenofusp alfa-eknm, used to treat children with Hunter syndrome (MPS II), a rare genetic disorder. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.